The low number of FD and SMA-PME case studies, a poor disease prognosis, and limited therapeutic options have made the development of an ACDase-deficient mouse models crucial for understanding these ultra-rare disorders and developing treatments. The gene discussed is ASAH1; the disease is progressive myoclonus epilepsy.